Business
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial in Alzheimer’s disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker engagement, and clinical efficacy of XPro™ (XPro1595, pegipanermin) in patients with mild Alzheimer’s disease characterized by bioma
About this update from Inmune Bio Inc.
[{"type":"image","alt":"INmune Bio, Inc.","displaySize":"","headline":null,"caption":"INmune Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_RfkNrUuo7An1sANp.xPfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_RfkNrUuo7An1sANp.xPfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60}},"lazy":false},{"type":"text","content":"Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial in Alzheimer’s disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker engagement, and clinical efficacy of XPro™ (XPro1595, pegipanermin) in patients with mild Alzheimer’s disease characterized by biomarkers of inflammation. In a pre-specified analysis of the protocol-defined Alzheimer’s Disease with inflammation (ADi) subgroup, XPro™ showed directionally consistent benefit across cognitive, global, functional, behavioral, and biomarker endpoints over 24 weeks, with no amyloid-related imaging abnormalities (ARIA) observed.","length":832,"tagName":"p"},{"type":"text","content":"The publication, titled “XPro1595 in Early Alzheimer’s Disease with Inflammation: Results from the Phase 2 MINDFuL Trial,” discusses how XPro™ demonstrated consistent positive trends in a pre-specified enriched subpopulation (n=100) with amyloid-beta positivity and two or more inflammation biomarkers (hsCRP, ESR, HbA1c, or APOE ε4 allele). The paper further highlights the effect sizes (Cohen’s d) up to 0.27 across cognitive (EMACC, International Shopping List Test), Patient-Reported Outcomes (Goal Attainment), behavioral (Neuropsychiatric Inventory), and biomarker endpoints (pTau217 and GFAP), directionally consistent with an XPro™ treatment effect. These findings support prioritization of the enriched population in future studies to optimize det...